Clémence Ginet

发表

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib

G. Robert, P. Auberger, J. Cassuto, 2012, Oncotarget.

BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia

H. Dombret, P. Rohrlich, P. Fenaux, 2017, Oncotarget.

Inhibition of Noninfectious Uveitis Using Intravenous Administration of Collagen II-Specific Type 1 Regulatory T Cells.

A. Foussat, H. Asnagli, J. Gertner-dardenne, 2015, Investigative ophthalmology & visual science.

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia

A. Stamatoullas, P. Rohrlich, N. Mounier, 2019, International Journal of Molecular Sciences.

DNA Damage and the Activation of the p53 Pathway Mediate Alterations in Metabolic and Secretory Functions of Adipocytes

P. Froguel, J. Tanti, P. Auberger, 2016, Diabetes.

Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway

G. Robert, P. Auberger, S. Tartare-Deckert, 2012, Oncotarget.

DNA damage and the activation of the p 53 pathway mediate alterations in metabolic and secretory functions of adipocytes Running title : DNA damage and p 53 in obese adipocytes

Franck, J. Tanti, P. Auberger, 2017 .

DNA damage and the activation of the p53 pathway mediate alterations in metabolic and secretory functions of adipocytes Running title: DNA damage and p53 in obese adipocytes

P. Froguel, J. Tanti, P. Auberger, 2016 .

Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation

R. Ballotti, T. Zenz, G. Robert, 2013, Haematologica.

Differentiation inducing factor 3 mediates its anti-leukemic effect through ROS-dependent DRP1-mediated mitochondrial fission and induction of caspase-independent cell death

G. Robert, P. Auberger, T. Cluzeau, 2016, Oncotarget.

Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib

G. Robert, P. Auberger, P. Hofman, 2014, Oncoscience.